-transparent.png){kind=logo}
Twenty-five women with advanced breast carcinoma refractory to first-line chemotherapy entered a phase II trial to evaluate the efficacy of ifosfamide and carboplatin. Additionally the trial assessed the clinical usefulness of oral 2-mercaptoethane sulfonate (mesna) for urothelial protection. Two partial remissions were observed (8%); toxicity was significant but acceptable, with no treatment-related deaths. The combination of ifosfamide and carboplatin had little activity as the second-line treatment in our population of patients with heavily pretreated metastatic breast cancer. Oral mesna was effective for urothelial protection, permitting outpatient administration of ifosfamide.
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
November 1987,
Cancer treatment reports,
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
May 1985,
Cancer treatment reports,
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
August 1998,
American journal of clinical oncology,
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
May 1989,
European journal of cancer & clinical oncology,
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
January 1994,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
June 1987,
Cancer treatment reports,
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
September 2015,
Anticancer research,
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
July 1995,
Annals of oncology : official journal of the European Society for Medical Oncology,
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
August 1996,
Annals of oncology : official journal of the European Society for Medical Oncology,
M Turrill, and
D V Spicer, and
A S Kelley, and
R L Herman, and
C A Russell, and
F M Muggia
November 1992,
Investigational new drugs,
